Job Location:
New Delhi,
India
Sunday, August 31, 2014
Dr B R Ambedkar National Institute of Technology, Jalandhar Walk-in for Assistant Professors - Sept. 4 ---"D5"
| Employer Name: | Dr B R Ambedkar National Institute of Technology |
| Employer Address: | N.I.T. Post Office, Jalandhar - 144011, Punjab, India. |
| Email: | NA |
| URL: | www.nitj.ac.in |
| Phone: | NA |
| Required Skills: | Teaching, Fluency in English |
| Required Experience: | 0+ years |
| Required Education: | M.E/M.Tech/Ph.D in Civil Engineering |
| Job Location: | Jalandhar, Punjab (View Jobs in Jalandhar, Jobs in Punjab) |
Hindu College, Recruitment of Assistant Professor and Guest Lecturer, Walk-in "D4"
Hindu College, New Delhi has advertised for the recruitment of Assistant Professor and Guest Lecturer job vacancies. Eligible and interested candidates are requested to walk-in on 04th and 05th September 2014. Learn more information below.
| Employer Name: | Hindu College, New Delhi |
| Employer Address: | University Enclave, Delhi - 110007, India. |
| Email: | hinducol@del3.vsnl.net.in |
| URL: | www.hinducollege.org |
| Phone: | 27667184 |
| Required Skills: | Teaching, Fluency in English |
| Required Experience: | 0+ years |
| Required Education: | M.Sc/M.Phil/Ph.D |
| Job Location: | New Delhi (View Jobs in New Delhi) APPLY |
Walk in for Medical graduate Freshers for Medical billing and sorting Noida/ Greater Noida For B.Pharm. (Pharmacy), B.Sc. (Science), BDS (Dental Surgery) "D1"
- 0 to 1 yrs
- Rs 1.20 - 1.35 Lacs p.a.
- Noida/ Greater Noida
- fresher graduate backend claims bpo non voice BA B.Com BBA insuranceB.Pharma BDS BUMS BHMS medical
- Doctors/Nurses/Medical Professional
- Healthcare
- Medical billing and sorting
- B.Pharm. (Pharmacy), B.Sc. (Science), BDS (Dental Surgery)
- 30
Job Description
HIRING FOR MEDICAL BILLING & SORTING PROFILE
- Eligibility: B.Pharma/BDS/BUMS/BHMS/BA/B.Sc/BBA/B.Com (B.Tech/BCA are not eligible)
- Candidate should not be undergraduate.
- Work Location: Noida
- Shifts: Day shift (8AM - 5PM)
- Good communication skills are must.
- Salary upto 1,40,000 per annum.
- Good working knowledge of MS Office 2010 suite (Word, Excel, PowerPoint) and proficiency in execution
- Ability to use the desktop computer system efficiently Basic IT knowledge and familiarity of operating systems (Windows 98/10)
- Good knowledge of using Internet, web browser, search engine, etc.
- Overview of US Insurance Industry
- Knowledge of US Culture Data gathering and numerical ability skills
- Communication skills - oral and written proficiency in English language
- Problem solving skills
- Business awareness
- Teamwork
- Adaptability
- Work standards
Desired Candidate Profile
WALK-IN INTERVIEWSDay: Monday to Saturday
Time: 11AM to 3PM
Contact Person / Reference - Eshita Kalia - 09811530040
Write 'Eshita Kalia' on top of your CV for reference.
Carry your CV, photograph and original ID proof with you.
Venue:
Noida
Genpact, Upper ground floor, Tower 8, Unitech Info Park, ITES SEZ, Sector 135, Noida
Landmark: Metlife building
Nearest Metro station : Botanical Garden
Genpact Bus service available from Botanical Garden Mtero station at 10.15/10.45
Learn CR, CDM & PV.
Fill this form to get to know the opportunities in Clinical Research Industry. You can join Short term program and build your career.
Screen reader support enabled.
Saturday, August 30, 2014
Exclusively for PHDp Group members-- Attend a free Introductory session on "Career opportunities in Clinical Research & Pharmacovigilance" @ CLINI INDIA NOIDA, on 6 & 7 Sept.2014 in Association with PHDp group "APPLY NOW"
CLICK HERE TO JOIN GROUP
INTRODUCTORY SESSION ON CLINICAL RESEARCH AND PHARMACOVIGILANCE
Screen reader support enabled.
PHARMA NEWS - Click here to see all recent News about Pharma Industry @ one Place - "D2"
Roche acquires respiratory therapy firm at $8.3 bn -
InterMune's lead medicine pirfenidone is approved for idiopathic pulmonary fibrosis in the EU and Canada -
Singapore: Global biopharmaceutical company, Roche, has acquired InterMune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, at USD8.3 billion. InterMune's lead medicine pirfenidone is approved for idiopathic pulmonary fibrosis (IPF) in the EU and Canada and under regulatory review in the United States. IPF is a progressive, irreversible and ultimately fatal disease characterized by progressive loss of lung function due to fibrosis, or scarring, in the lungs. Roche markets Pulmozyme and Xolair in the US and has other novel therapeutic medicines targeting respiratory diseases in clinical development. Commenting on the transaction, Mr Severin Schwan, CEO, Roche, said, "We are very pleased that we reached this agreement with InterMune. Our offer provides significant value to InterMune's shareholders and this acquisition will complement Roche's strengths in pulmonary therapy. We look forward to welcoming InterMune employees into the Roche Group and to making a difference for patients with idiopathic pulmonary fibrosis, a devastating disease." Mr Dan Welch, chairman, CEO and president, InterMune, said, "This merger recognizes the significant value created by our team's commitment, hard work and execution for more than a decade to develop and commercialize treatment options for IPF patients and their families. Roche shares our passion and commitment to the IPF community and to ensuring that pirfenidone is available as quickly as possible to patients in the United States, pending FDA approval. Roche's global resources and scale will not only facilitate and accelerate our ability to deliver pirfenidone to more patients around the world, but also to realize our joint vision to bring additional innovative therapies to patients with respiratory diseases." Pirfenidone has been marketed by InterMune in the EU and Canada as Esbriet since regulatory approval in 2011 and 2012 respectively. After previous regulatory review in the USA in 2010, the Food and Drug Administration (FDA) recommended an additional Phase 3 clinical trial to support the efficacy of pirfenidone. -
FDA approves single dosage HIV drug -
Singapore: The US Food and Drug Administration (FDA) has approved US-based ViiV Healthcare's single dose Triumeq tablets for treatment of HIV-1 infection. Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. Triumeq alone is not recommended for use in patients with current or past history of resistance to any components of Triumeq. Triumeq alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in Triumeq is insufficient in these populations. Before initiating treatment with abacavir-containing products, screening for the presence of a genetic marker, the HLA-B 5701 allele, should be performed in any HIV-infected patient, irrespective of racial origin. Products containing abacavir should not be used in patients known to carry the HLA-B5701 allele. Dr Dominique Limet, chief executive officer, ViiV Healthcare, said, "The approval of Triumeq offers many people living with HIV in the US, the first single-pill regimen containing dolutegravir. ViiV Healthcare is committed to delivering advances in care and new treatment options to physicians and people living with HIV. We are proud to announce this important milestone, marking the second new treatment to be approved in the US from our pipeline of medicines." -
US FDA approves GSK’s asthma drug -
GlaxoSmithKline’s inhaled corticosteroid Arnuity Ellipta (fluticasone furoate) has been granted approval by the US Food and Drug Administration -
Singapore: GlaxoSmithKline (GSK) has announced that the United States Food and Drug Administration (US FDA) has approved Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. However, Arnuity is not indicated for relief of acute bronchospasm. It has been approved in the dosages of 100 mcg and 200 mcg. It is administered once daily via the dry powder inhaler Ellipta, which is also used across a range of other approved respiratory medicines in the GSK portfolio. "The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expanding the range of medicines that we offer to physicians and appropriate patients," Mr Darrell Baker, SVP and head, GSK global respiratory franchise, said. The efficacy and safety of this drug have been evaluated in more than 3,600 patients with asthma. -
China to offer personalized chemotherapy-
Fosun diagnostics has joined hands with Saladax Biomedical to launch MyCare assays-a customized chemotherapy dosing for Chinese cancer patients -
Singapore: China-based Fosun diagnostics and Saladax Biomedical announced the launch of MyCare assay tests for chemotherapy in China. Saladax Biomedical in partnership with Fosun diagnostics has designed customized chemotherapy dosing for patients. MyCare tests provide oncologists with specific information about each patient's exposure to chemotherapy drug, helping the doctor to make informed decisions on dose adjustments. These tests were designed after extensive patient trials conducted by Saladax. Mr Ted Zhu, CEO, Fosun Diagnostics, said, "MyCare assays are blood tests that provide healthcare practitioners with a way to manage each patient individually and design the best suitable treatment for them." He added that such personalized cancer care would help in increasing the effectiveness of chemotherapy and reducing side effects. MyCare kits have received approval from Chinese Food and Drug Administration. Fosun aims to manage distributors and work directly with large healthcare facilities and oncologists to make this technology available to the large Chinese market. Mr Zhu added that he was very pleased to bring this personalized care to the Chinese. Mr Kevin M Harter, president and CEO of Saladax said, "The launch of Saladax's MyCare tests in China represents an important milestone for Saladax. With Fosun partnering us, we have high expectations from this market." The MyCare technology platform covers 80 percent to 90 percent of the routine anti-tumor drug monitoring market. For its accurate and authentic results, the MyCare technology platform and product portfolio are in a leading position in the world, for cancer care. -
Learn CR, CDM & PV. -DELHI
Fill this form to get to know the opportunities in Clinical Research Industry. You can join Short term program and build your career.
Screen reader support enabled.
Friday, August 29, 2014
Scope of Career in Clinical Research Industry In India- Freshers must see for info. about career prospects in Industry & comment below for guidance -Click here "D9"
India is becoming a hub for clinical research; the demand for professionals in this field is growing rapidly. There is a massive demand for clinical Research professionals, making it an interesting career option with massive growth potential.
Clinical research is all set to become the next big thing in India. A large population with a substantial workforce and cost benefits influence multinationals to set up research facilities here. Besides due to the prevalence of a large variety of diseases, including widespread cases of cancer and diabetes India is viewed the world over as the ideal location for clinical research trials for the pharmaceutical industry. |
.
|
v What is Clinical Research?
|
A clinical research is a scientific study of the effects, risks, efficacy and benefits of a medicinal product. These are carried out prior to the release of the medicine in the market. These trials are undertaken at various stages and studies are conducted after the launch of a new product to monitor safety and side effects during large-scale use. Clinical trials are conducted by pharmaceutical companies or contract research organizations (CRO's) on their behalf. It is this sector that is driving the growth in clinical research in India. So, what does one need to become a part of this rapidly growing industry? |
v Eligibility:
|
A Pharma, Life science or Medical graduate/Postgraduate is eligible to enter this field. Ideally the industry is looking for science graduates from pharmacy, medicine, life science and bioscience. Within bioscience too there are various other fields such as botany, zoology, biochemistry and genetics. Anybody who fulfils these criteria can join the industry. |
v Who can be your Employer:
|
You can be employed by either of the following-
|
ü Contract Research Organization (CROs)
|
ü IT Companies
|
ü Hospitals
|
ü Site Management Organization
|
ü Wellness Organization etc.
|
Clinical Research Career Prospects
The discipline of Drug Development Clinical Research has created multiple cross functional opportunities in the Industry, namely - |
● Clinical Research Associate (CRA)● Clinical Research Coordinator (CRC)● Clinical Data Manager● Pharmacovigilance / Drug Safety Professional● Medical/Regulatory affairs● Medical Writing Professional● Biostatistician
|
●Investigator● Monitor● Bioavailability & Bioequivalence Expert● Clinical Project Manager● Trial Supplies / Logistics Manager● Quality Assurance Auditor● Clinical Trial Documentation in-charge● Business Development Personnel
|
v Job Profile:
Clinical Research branches off into various categories at the entry level. The most common entry-level position is that of a Clinical Research Associate (CRA). The role of a CRA is varied, |
Ø They are key participants in the design, implementation and monitoring of clinical trials
|
Ø They shoulder the responsibility of planning and implementing all activities required to conduct and monitor complex clinical trials and ensure that Good Clinical Practices are followed.
|
Ø They assist in preparation of presentations and manuscripts of scientific meetings and technical journals and attend scientific/professional meetings and training courses as appropriate.
|
CRM are Clinical Research Managers,
They supervise design and writing of protocols, case report forms and informed consent forms for clinical trials. They ensure that Case Report Forms are reviewed in a timely fashion and submitted to the data management group. There are other posts too such as Clinical Research Coordinator, Business Development Manager, Clinical Research Investigator, Clinical Data Manager etc. |
In Pharmacovigilance you can start your Career as Drug Safety Associate, Safety Processing Expert.
|
In Data Management you can start your Career as Clinical Data Analyst
|
v Remuneration:
|
There is high demand for trained professionals in this field; the pay package is impressive at the entry level. |
Ø Fresher can expect a pay packet of around three lac or more per annum.
|
Ø If you have a master's degree backing your qualifications, then the amount is almost double.
|
Ø Clinical research is an industry where experience counts, thus the longer you are in this field; higher the salary you can expect.
|
v Growth Prospects:
There are various growth opportunities along the way for those willing to learn. For those interested in serious Research work can also join Phd and get into further research. |
Candidates who have any query can Call me or Message @ 092 898 70004 for any guidance.
Dheeraj Awasthi
Manager
CLINI INDIA DELHI
|
Learn CR, CDM & PV. - Fill the form for any Mentorship by experts
Fill this form to get to know the opportunities in Clinical Research Industry. You can join Short term program and build your career.
Screen reader support enabled.
Thursday, August 28, 2014
DCR Puttur Entomology SRF Walk Ins B4
DIRECTORATE OF CASHEW RESEARCH
(Formerly National Research Centre for Cashew)
(Indian Council of Agricultural Research)
Puttur, D.K., 574 202, KARNATAKA WALK – IN – INTERVIEW It is proposed to fill up two temporary posts of Senior Research Fellow at this Directorate on contractual basis. Candidates having the prescribed qualifications as detailed below may appear for a Written test/Interview on 24.9.2014 (Wednesday) at 11.30 AM. 1. Name of the post Senior Research Fellow - Two Posts 2. Name of the Projects a) “ORP on management of sucking pests in Horticultural Crops”- 1 Post Essential Qualification M.Sc. (Ag.)in Agricultural Entomology or M.Sc. Zoology/Applied Zoology or M.Sc. Bio-Science with specialization in Zoology or Entomology b) “ Micronutrient management in horticultural crops for enhancing yield and quality’’-
1 Post Essential Qualification M.Sc. (Ag.) in Soil Science and Agril. Chemistry or M.Sc. Chemistry/ Biochemistry/MicrobiologyDesirable Research Experience 3 Duration of the Projects Till March 2017 or termination of Projects whichever is earlier. 4 Upper Age limit 35 years for Men, 40 years for Women- as on 31.8.2014 (Relaxation in age to SC/ST/OBC as per Govt. of India/ICAR norms) 5 Emoluments ` 16,000 p.m. +HRA (as admissible) for First two years `18,000 p.m. +HRA (as admissible) for third year. 6 Location of the Project Directorate of Cashew Research, Puttur, 574202, DK, Karnataka Terms & conditions: 1. The candidates should bring a copy of biodata, original certificates of qualifications and age, one set of self attested photocopies of all the certificates, experience certificate and latest passport size photograph.
2. No objection certificate from the employer in case he/she is in employment elsewhere.
3. Candidates may register their candidature from 9.30 A.M to 11.00 AM only 4. No TA will be paid for the journey to attend the test/ interview.
5. The Director’s decision will be final and binding on all aspects.
CLICK HERE FOR MORE INFO